Committee opinion no. 524: Opioid abuse, dependence, and addiction in pregnancy

Obstetrics and Gynecology

Volumn 119, Issue 5, 2012, Pages 1070-1076

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CODEINE; DIAMORPHINE; KETOROLAC; METHADONE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

BIRTH DEFECT; CONGENITAL HEART DISEASE; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; ENVIRONMENTAL EXPOSURE; EPIDURAL ANESTHESIA; FETUS DISEASE; HUMAN; LABOR PAIN; LIVER DYSFUNCTION; METHADONE TREATMENT; OBSTETRIC ANALGESIA; OPIATE ADDICTION; PHYSICIAN; POSTOPERATIVE PAIN; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SPINAL ANESTHESIA; TERATOGENICITY; WITHDRAWAL SYNDROME; ARTICLE; FEMALE; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 84860143470     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318256496e     Document Type: Review

References (37)

1. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville (MD): SAHMSA; 2011. Available at http://www.oas.samhsa. gov/NSDUH/2k10NSDUH/2k10Results.pdf. Retrieved February 9, 2012.
2. Azadi A, Dildy GA 3rd. Universal screening for substance abuse at the time of parturition. Am J Obstet Gynecol 2008; 198:e30-2.
3. National Institute on Drug Abuse. Research report series-heroin abuse and addiction. Bethesda (MD): NIDA; 2005. Available at: http://www.drugabuse.gov/ publications/research-reports/heroin-abuse-addiction. Retrieved February 24, 2012.
4. National Institute on Drug Abuse. Commonly abused prescription drugs. Bethesda (MD): NIDA; 2011. Available at https://www.drugabuse.gov/sites/default/ files/rx-drugs-placemat-508c-10052011.pdf. Retrieved February 9, 2012.
5. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25:139-51.
6. Rothman KJ. Causes. Am J Epidemiology 1976;104:587-92.
7. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985;313:347-52. (Pubitemid 15046366)
8. Bracken MB. Drug use in pregnancy and congenital heart disease in offspring. N Engl J Med 1986; 314:1120. (Pubitemid 16137094)
9. Shaw GM, Malcoe LH, Swan SH, Cummins SK, Schulman J. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. Eur J Epidemiol 1992;8:757-60.
10. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981;58:336-44. (Pubitemid 11014280)
11. Jick H, Holmes LB, Hunter JR, Madson S, Stergachis A. First-trimester drug use and congenital disorders. JAMA 1981;246:343-6. (Pubitemid 12251384)
12. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. National Birth Defects Prevention Study. Am J Obstet Gynecol 2011. DOI: 10.1016/j.ajog.2010.12.039.
13. Center for Substance Abuse Treatment. Medicationassisted treatment for opioid addiction during pregnancy. In: SAHMSA/CSAT treatment improvement protocols. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2008. Available at: http://www.ncbi. nlm.nih.gov/books/NBK26113. Retrieved February 9, 2012.
14. Ewing H. A practical guide to intervention in health and social services with pregnant and postpartum addicts and alcoholics: theoretical framework, brief screening tool, key interview questions, and strategies for referral to recovery resources. Martinez (CA): The Born Free Project, Contra Costa County Department of Health Services; 1990.
15. Chang G, Orav EJ, Jones JA, Buynitsky T, Gonzalez S, Wilkins-Haug L. Self-reported alcohol and drug use in pregnant young women: a pilot study of associated factors and identification. J Addict Med 2011;5:221-6.
16. Substance abuse reporting and pregnancy: the role of the obstetrician-gynecologists. Committee Opinion No. 473. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;117:200-1.
17. Alto WA, O'Connor AB. Management of women treated with buprenorphine during pregnancy. Am J Obstet Gynecol 2011;205:302-8.
18. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985;233: 1-6. (Pubitemid 15083518)
19. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116:665-71.
20. Velez ML, Jansson LM, Schroeder J, Williams E. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res 2009;66:704-9.
21. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, et al. Methadone dose and neonatal abstinence syndrome-systemic review and meta-analysis. Addiction 2010;105:2071-84.
22. Institute of Medicine. Federal regulation of methadone treatment. Washington DC: National Academy Press; 1995.
23. Drug addiction treatment act of 2000, Pub. L. No. 106-310 § 3502, 114 Stat. 1223-7. (2000).
24. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. Buprenorphine/Naloxone Collaborative Study Group. N Engl J Med 2003;349:949-58. (Pubitemid 37064768)
25. Johnson RE, Jones HE, Fisher G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-101. (Pubitemid 36556063)
26. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320-31.
27. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008;17:372-86.
28. Substance Abuse and Mental Health Services Administration. Frequently asked questions: applying the substance abuse confidentiality regulations to health information exchange (HIE). Rockville (MD): SAHMSA; 2010. Available at: http://www.samhsa.gov/healthprivacy/docs/EHR-FAQs. pdf. Retrieved February 12, 2012.
29. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007;110:261-6. (Pubitemid 47356649)
30. Jones HE, O'Grady K, Dahne J, Johnson R, Lemoine L, Milio L, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009;35:151-6.
31. Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006;15:258-9.
32. Wojnar-Horton RE, Kristensen JH, Yapp P, Ilett KF, Dusci LJ, Hackett LP. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol 1997;44:543-7. (Pubitemid 27517480)
33. Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103. (Pubitemid 32293533)
34. Jones HE, Johnson RE, O'Grady KE, Jasinski DR, Tuten M, Milio L. Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med 2008; 2:103-7.
35. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-101. (Pubitemid 36556063)
36. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol 1984; 6:271-5. (Pubitemid 15207057)
37. Hans SL. Developmental consequences of prenatal exposure to methadone. Ann N Y Acad Sci 1989;562:195-207. (Pubitemid 19207752)